Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-α inhibitor, infliximab

British Journal of Dermatology

Volumn 152, Issue 3, 2005, Pages 552-555

  Hertl, Michael S ^a   Haendle, I ^a   Schuler, G ^a   Hertl, M ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Diabetes; Granuloma annulare; Infliximab; Treatment; Tumour necrosis factor

Indexed keywords

CLOFAZIMINE; DAPSONE; ETRETIN; GLUCOCORTICOID; INFLIXIMAB; RETINOID; TAZAROTENE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; CASE REPORT; ERYTHEMA; FEMALE; GRANULOMA ANNULARE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NECROBIOSIS LIPOIDICA; PRIORITY JOURNAL; SARCOIDOSIS; SIDE EFFECT; SKIN INFLAMMATION;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; GRANULOMA ANNULARE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 17444430358     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06371.x     Document Type: Article

References (20)

1. Smith MD, Downie JB, DiCostanzo D. Granuloma annulare. Int J Dermatol 1997; 36:326-33.
2. Tan HH, Goh CL Granuloma annulare: a review of 41 cases at the National Skin Centre. Ann Acad Med Singapore 2000; 29:714-18.
3. Penas PF, Jones-Caballero M, Fraga J et al. Perforating granuloma annulare. Int J Dermatol 1997; 36:340-18.
4. Feiner EI, Steinberg JB, Weinberg AG. Subcutaneous granuloma annulare: a review of 47 cases. Pediatrics 1997; 100:965-7.
5. Fayyazi A, Schweyer S, Eichmeyer B et al. Expression of IFN-γ, co-expression of TNFα and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare. Arch Dermatol Res 2000; 292:384-90.
6. Antony F, Holden CA. Sweet's syndrome in association with generalized granuloma annulare in a patient with previous breast carcinoma. Clin Exp Dermatol 2001; 26:668-70.
7. Ahmed AA, Nordlind K, Schultzberg M et al. Interleukin-1 alpha- and beta-, interleukin-6- and tumour necrosis factor-alpha-like immunoreactivities in chronic granulomatous skin conditions. Acta Derm Venereol 1994; 74:435-40.
8. Jacobi A, Manger B, Schuler G, Hertl M. Therapeutic application of the tumor necrosis factor-alpha inhibitors infliximab and etanercept in inflammatory skin disorders. J Deutsch Dermatol Ges 2003; 1:259-72.
9. LaDuca JR, Gaspari AA. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin 2001; 19:617-35.
10. Tan MH, Gordon M, Lebwohl O et al. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor α monoclonal antibody. Arch Dermatol 2001; 137:930-3.
11. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric antitumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354:1932-9.
12. Chaudari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357:1842-7.
13. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002; 61:298-304.
14. Marino MW, Dunn A, Grail D et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997; 22:8093-8.
15. Zganiacz A, Santosuosso M, Wang J et al. TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J Clin Invest 2004; 113:401-13.
16. Devos SA, van den Bossche N, de Vos M et al. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003; 206:388-90.
17. Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004; 63:318-20.
18. Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol 2004; 150:146-9.
19. Drosou A, Kirsner RS, Welsh E et al. Use of infliximab, an antitumor necrosis alpha antibody, for inflammatory dermatoses. J Cuton Med Surg 2003; 7:382-6.
20. Kolde G, Muche JM, Schulze P et al. Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica. Dermatology 2003; 206:180-1.